Vimarsana
Biggest News Aggregation in the World

Page 3 - Deric Dube News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Deric Dube. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Deric Dube Today - Breaking & Trending Today

Travere Therapeutics Reports Third Quarter 2023 Financial Results - Vimarsana News

Travere Therapeutics Reports Third Quarter 2023 Financial Results

          Received 430 new patient start forms for FILSPARI®  in the third quarter of 2023; demand and payer coverage continued to grow             Net product sales of FILSPARI...

NATIONAL ORGANIZATION FOR RARE DISORDERS HOSTS 2023 BREAKTHROUGH SUMMIT - Vimarsana News

NATIONAL ORGANIZATION FOR RARE DISORDERS HOSTS 2023 BREAKTHROUGH SUMMIT

/PRNewswire/ -- WHAT: Join the National Organization for Rare Disorders (NORD) Oct. 15-17, 2023 in Washington for the Rare Diseases and Orphan Products...

ZimAlloys set to fire up new furnaces after $40m injection - Vimarsana News

ZimAlloys set to fire up new furnaces after $40m injection

ONE of the country's largest ferrochrome producers, Zimbabwe Alloys (ZimAlloys) will next month return to production after a new shareholder injected close to U...

Ligand's Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control - Vimarsana News

Ligand's Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control

Ligand Pharmaceuticals Incorporated announced that its partner Travere Therapeutics, Inc. today released topline, two-year confirmatory secondary endpoint results from its pivotal, head-to-head...

Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan - Vimarsana News

Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan

FILSPARI® achieved a clinically meaningful difference vs. irbesartan in eGFR total slope [p= 0.058] and eGFR chronic slope [p=0.037]. Patients treated with FILSPARI over two years exhibited one of...